Urine Sediment Testing Global Market Report 2024

The urine sediment testing market size has grown strongly in recent years. It will grow from $1777.9 billion in 2023 to $1902.1 billion in 2024 at a compound annual growth rate (CAGR) of 7.0%. The growth observed in the historical period can be attributed to several factors, including advancements in laboratory practices enhancing the efficiency and accuracy of urine sediment testing, successful integration of this testing into clinical practices for diagnostic purposes, educational initiatives and training programs aimed at promoting its understanding and use, a focused emphasis on nephrology and urology driving the need for such testing methods, and the establishment of standardized testing protocols ensuring consistency and reliability in results.

The urine sediment testing market size is expected to see strong growth in the next few years. It will grow to $2566.4 billion in 2028 at a compound annual growth rate (CAGR) of 7.8%. The projected growth in the forecast period is expected to be fueled by various factors, including the increasing incidence of urinary tract disorders prompting a higher demand for urine sediment testing, the integration of artificial intelligence (AI) and machine learning technologies to enhance diagnostic capabilities, a trend towards point-of-care testing for quicker and more accessible diagnostics, a growing focus on preventive healthcare strategies, and the ongoing development of personalized medicine approaches. Key trends anticipated in the forecast period encompass the implementation of enhanced quality control measures to ensure the accuracy and reliability of urine sediment testing, the utilization of remote monitoring and telemedicine solutions for improved patient care, customization of testing protocols tailored to specific disorders, the development and application of AI-assisted analysis tools to assist in diagnostics, and a heightened emphasis on high-throughput screening methods to efficiently handle larger volumes of testing.

The rising number of elderly individuals, defined as those aged 60 and above, is expected to fuel the growth of the urine sedimentation testing market. Urine sediment testing plays a crucial role in benefiting the aging population by identifying renal illnesses and providing valuable information on aggravating factors, prognosis, pathogenic bacteria, and antibiotic vulnerability. According to a factsheet published by the World Health Organization in October 2021, the global population of individuals aged 60 and above is projected to reach 1.4 billion by 2030, up from 1 billion in 2020. This demographic shift highlights the increasing demand for healthcare services, including diagnostic tests such as urine sedimentation testing, to cater to the health needs of the elderly population.

The growing prevalence of chronic kidney diseases (CKD) is expected to contribute significantly to the expansion of the urine sediment testing market. Chronic kidney disease is characterized by the gradual damage and loss of function in the kidneys, impacting their ability to effectively filter blood. Urine sediment testing serves as a non-invasive and simple diagnostic tool to assess kidney health, aiding in the diagnosis and monitoring of CKD. According to data from the Centers for Disease Control and Prevention in May 2023, an estimated 35.3 million people in the United States have chronic kidney disease, with around 130,522 individuals starting treatment for end-stage kidney disease (ESKD) in 2020. Additionally, it is projected that approximately 786,800 people in the U.S. are living with end-stage renal disease (ESRD), with 71% expected to undergo dialysis treatment in 2021. The increasing prevalence of chronic kidney diseases highlights the critical role of urine sediment testing in disease diagnosis and management, thereby contributing to the growth of the market.

A prominent trend gaining traction is product innovation, with leading companies striving to introduce cutting-edge solutions to fortify their market positions. A notable example is Sysmex Corporation, a Japanese entity in this domain, which unveiled the UF-1500 Fully Automated Urine Particle Analyzer equipment in September 2022. This state-of-the-art apparatus offers distinct features, including an individualized view of diverse particles. The product is designed to provide a broader array of solutions tailored to customers' environments, facilitating standardization and scalability of urine testing, particularly in small and medium-sized facilities.

The competitive landscape of the urine sediment testing market is witnessing a strategic focus on the development of automated urinalysis systems by major industry players. One such illustration is the initiative undertaken by Beckman Coulter Inc., a US-based biomedical testing manufacturer, in October 2023. The company launched the DxU Iris Workcell, a fully automated urinalysis system poised to enhance operational efficiency by streamlining workflow and minimizing manual reviews to a mere 4%. Leveraging proprietary Digital Flow Morphology technology and Auto-Particle Recognition (APR) software, this system effectively isolates, identifies, and characterizes urine particles on the screen, thereby significantly reducing reliance on manual microscopy. The DxU Iris Workcell is not only technologically advanced but also user-friendly, boasting a design that necessitates minimal training for operation and maintenance.

In December 2021, Thermo Fisher Scientific Inc., a biotechnology research company headquartered in the United States, successfully completed the acquisition of PPD Inc. for a substantial sum of USD 17.4 billion. This strategic move positions Thermo Fisher Scientific Inc. to accelerate its endeavors in advancing life-changing pharmaceuticals, ultimately contributing to global patient welfare. PPD Inc., a prominent US-based entity, specializes in laboratory and lifecycle management services, encompassing areas such as urine sediment testing. The acquisition is anticipated to enhance Thermo Fisher Scientific Inc.'s capabilities and offerings in the biotechnology and pharmaceutical sectors.

Major companies operating in the urine sediment testing market report are Medtronic plc, Abbott Laboratories, Siemens AG, General Electric, Becton Dickinson and Company, Bio-Rad Laboratories Inc., F Hoffmann-La Roche Ltd., Sysmex Corporation, Beckman Coulter Inc., Thermo Fisher Scientific Inc., ARKRAY Inc., BioMérieux SA, Mindray Medical International Limited, URIT Medical Electronic Co Ltd., 77 Elektronika Kft, ACON Laboratories Inc., Analyticon Biotechnologies AG, DIRUI Industrial Co. Ltd., HUMAN Gesellschaft für Biochemica und Diagnostica GmbH, Menarini Diagnostics, Shenzhen Mindray Bio-Medical Electronics Co. Ltd., URIT Medical Electronic Group Co. Ltd., YD Diagnostics Corporation, Trinity Biotech plc, A S Chemicals, Ceg Test House, Chase Corporation, Quidel Corporation, Standard Analytical Laboratory Pvt. Ltd., Thermo Fisher Scientific Inc..

North America was the largest region in the urine sediment testing market in 2023. The regions covered in the urine sediment testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the urine sediment testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary types of products used for urine sediment testing include fully automatic urine sediment analyzers and semi-automatic urine sediment analyzers. Fully automatic urine sediment analyzers are capable of storing clinical data, dry chemical indices, results from microscopic examinations, and other relevant information. They are utilized across various applications to detect urinary tract infections, diabetes, kidney diseases, hypertension, and other related conditions. These analyzers are employed by a range of end-users, including hospitals, diagnostics centers, clinics, ambulatory surgical centers, educational institutes, and similar healthcare facilities.

The urine sediment testing drugs market research report is one of a series of new reports that provides urine sediment testing drugs market statistics, including urine sediment testing drugs industry global market size, regional shares, competitors with a urine sediment testing drugs market share, detailed urine sediment testing drugs market segments, market trends and opportunities, and any further data you may need to thrive in the urine sediment testing drugs industry. This urine sediment testing drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.